Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Taki Galanis & Geno J. Merli. (2013) Direct Thrombin and Factor Xa Inhibition for Stroke Prevention in Patients With Atrial Fibrillation. Hospital Practice 41:1, pages 26-36.
Read now
Read now
Michelle T. Martin & Edith A. Nutescu. (2011) Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Current Medical Research and Opinion 27:11, pages 2123-2131.
Read now
Read now
Articles from other publishers (17)
Carmen Suárez Fernández, Jorge F. Gómez Cerezo, Inmaculada Gómez Arrayás, Lourdes Betegón Nicolás, Marina de Salas-Cansado & Carlos Rubio-Terrés. (2013) Análisis de coste-efectividad de apixaban frente a enoxaparina en la prevención del tromboembolismo venoso en la artroplastia total de rodilla o cadera. PharmacoEconomics Spanish Research Articles 10:4, pages 107-118.
Crossref
Crossref
Kunihiro Hosaka, Shu Saito, Takao Ishii, Takanobu Sumino, Keinosuke Ryu, Gen Suzuki, Takashi Suzuki & Yasuaki Tokuhashi. (2013) Safety of Fondaparinux Versus Enoxaparin After TKA in Japanese Patients. Orthopedics 36:4.
Crossref
Crossref
A. John Camm. (2013) Managing anticoagulation for atrial fibrillation: current issues and future strategies. Journal of Internal Medicine 273:1, pages 31-41.
Crossref
Crossref
Geoffrey D. Barnes, Scott Kaatz, Vlad Golgotiu, Xiaokui Gu, Adam Leidal, Abdallah Kobeissy, Brian Haymart, Eva Kline-Rogers, Jay Kozlowski, Steve Almany, Tom Leyden & James B. Froehlich. (2012) Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). Journal of Thrombosis and Thrombolysis 35:1, pages 10-14.
Crossref
Crossref
J.F. Gómez-Cerezo, I. Gómez-Arrayás, C. Suárez-Fernández, L. Betegón-Nicolás, M. de Salas-Cansado & C. Rubio-Terrés. (2012) Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement. Revista Española de Cirugía Ortopédica y Traumatología (English Edition) 56:6, pages 459-470.
Crossref
Crossref
J.F. Gómez-Cerezo, I. Gómez-Arrayás, C. Suárez-Fernández, L. Betegón-Nicolás, M. de Salas-Cansado & C. Rubio-Terrés. (2012) Análisis coste-efectividad de apixaban frente a dabigatrán en la prevención de la tromboembolia venosa en pacientes intervenidos de artroplastia total de rodilla o de cadera. Revista Española de Cirugía Ortopédica y Traumatología 56:6, pages 459-470.
Crossref
Crossref
Carlos Alves, Francisco Batel-Marques & Ana Filipa Macedo. (2011) Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty. Journal of Cardiovascular Pharmacology and Therapeutics 17:3, pages 266-276.
Crossref
Crossref
Davide Imberti, Massimo Gallerani & Roberto Manfredini. (2012) Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Journal of Thrombosis and Thrombolysis 34:2, pages 208-213.
Crossref
Crossref
Sander S. van Berkel, Bas van der Lee, Floris L. van Delft, Rob Wagenvoord, H. Coenraad Hemker & Floris P. J. T. Rutjes. (2012) Fluorogenic Peptide-Based Substrates for Monitoring Thrombin Activity. ChemMedChem 7:4, pages 606-617.
Crossref
Crossref
D. Paradiso, C. Conti & P. D’Errico. (2012) Estrazioni dentarie in regime ambulatoriale in pazienti in terapia con anticoagulanti orali. Dental Cadmos 80:2, pages 65-71.
Crossref
Crossref
Walter Ageno, Alex Spyropoulos & Alexander Turpie. (2017) Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thrombosis and Haemostasis 107:06, pages 1027-1034.
Crossref
Crossref
Isabelle Djaffar-JureidiniNabil ChamseddineSose KeleshianRania NaoufalLaila ZahedNoha Hakime. (2011) Pharmacogenetics of Coumarin Dosing: Prevalence of CYP2C9 and VKORC1 Polymorphisms in the Lebanese Population. Genetic Testing and Molecular Biomarkers 15:11, pages 827-830.
Crossref
Crossref
Richard J. Friedman. (2011) Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials. Orthopedics 34:10, pages 795-804.
Crossref
Crossref
Arthur W. Bracey, Meredith A. Reyes, Alice J. Chen, Maryam Bayat & Paul M. Allison. (2011) How do we manage patients treated with antithrombotic therapy in the perioperative interval. Transfusion 51:10, pages 2066-2077.
Crossref
Crossref
Jessica A Bovio, Steven M Smith & John G Gums. (2011) Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease. Annals of Pharmacotherapy 45:5, pages 603-614.
Crossref
Crossref
J.M. Calvo Romero & E.M. Lima Rodríguez. (2011) Indicaciones del dabigatrán. SEMERGEN - Medicina de Familia 37:5, pages 252-254.
Crossref
Crossref
Teresa Gómez García, Javier de Miguel Díez & Adolfo Baloira Villar. (2011) Circulación pulmonar: ¿qué ha aportado el año 2010?. Archivos de Bronconeumología 47, pages 7-11.
Crossref
Crossref